期刊文献+

脑胶质瘤术后放疗联合替莫唑胺化疗同步与序贯治疗的对比 被引量:2

Contrast research of radiotherapy combined with synchronizing chemotherapy and sequential chemotherapy of temozolomide after glioma surgery
在线阅读 下载PDF
导出
摘要 目的探讨脑胶质瘤术后放疗联合替莫唑胺化疗同步与序贯疗法治疗的临床效果。方法将我院收治的46例脑胶质瘤术后患者,随机分为对照组和观察组。对照组采用放疗联合替莫唑胺序贯疗法治疗,观察组采用放疗联合替莫唑胺同步疗法治疗。比较2组无病生存期、治疗过程中不良反应发生情况。结果观察组无病生存期显著长于对照组,差异有统计学意义(P<0.05)。2组不良反应发生率经统计学分析,差异无统计学意义(P>0.05)。结论同步放化疗可显著延长患者的无病生存期,不增加不良反应,为脑胶质瘤术后较好的治疗方案。 Objective To study the clinical effect of the radiotherapy combined with synchronizing chemotherapy or se-quential chemotherapy of temozolomide after glioma surgery.Methods 46 patients after glioma surgery were randomly divided into control group and observation group. Control group adopted radiotherapy combined with temozolomide sequential therapy , observation group adopted radiotherapy combined with temozolomide synchronizing therapy. disease free survival time ,adverse reactions of two groups were compared in the process of treatment.Results free survival time of observation group were signif-icantly longer than that of control group ,the difference was statistically significant (P〈0.05). There was no significant differ-ence in incidence of adverse reactions of two groups ,(P〉0.05).Conclusion concurrent chemoradiotherapy can significantly prolong the disease free survival time of patients with cerebral gliomas after surgery ,without increasing side effects ,it’s a bet-ter treatment for glioma surgery.
出处 《中国实用神经疾病杂志》 2014年第14期23-25,共3页 Chinese Journal of Practical Nervous Diseases
关键词 脑胶质瘤 放疗 无病生存期 替莫唑胺 同步 序贯 Glioma Radiation therapy Disease free survival Temozolomide Synchronization Sequential
作者简介 通讯作者
  • 相关文献

参考文献10

  • 1毛德强,戴勤弼.58例脑胶质瘤术后同步放化疗的疗效观察[J].中国临床神经科学,2010,18(4):419-422. 被引量:2
  • 2Wang J, Sai K, Chen FR, et al. miR 181b modulates glioma cell sensitivity to temozolomide by targeting MEK1[J]. Cancer Chemother Pharmacol, 2013,5(10):1 684-1 689.
  • 3毛德强,潘玲,戴勤弼,娄四龙,卞伟,陈杰,阮健.脑胶质瘤术后放疗联合同步超选动脉化疗的近期疗效观察[J].重庆医科大学学报,2011,36(6):759-761. 被引量:10
  • 4Yust Katz S, Liu D, Yuan Y, et al. Phase 1/lb study of lona- farnib and temozolomide in patients with recurrent or temozolo mide refractory glioblastoma[J]. Cancer, 2013, 4 ( 30 ) : 149- 153.
  • 5Hart MG, Garside R, Rogers G, et al. Temozolomide for high grade glioma[J]. Cochrane Database Syst Rev, 2013,4 (13) : 1 284-1 289.
  • 6程元芝,张海宝,王姗.三维适形放疗联合替莫唑胺化疗用于恶性脑胶质瘤术后疗效观察[J].浙江临床医学,2012,14(12):1500-1502. 被引量:6
  • 7Quann K, Gonzales DM, Mercier I, et al. Caveolin-1 is a neg- ative regulator of tumor growth in glioblastoma and modulates chemosensitivity to temozolomide[J]. Cell Cycle, 2013, 12(10):18- 23.
  • 8马杰.三维适形放疗联合替莫唑胺治疗恶性脑胶质瘤疗效评价[J].华北煤炭医学院学报,2010,12(5):627-628. 被引量:3
  • 9Kumar DM, Patil V, Ramachandran B, et al. Temozolomide modulated glioma proteome: Role of Interleukin-1 receptor as- sociated kinase-4 (IRAK4) in chemosensitivity [J] . Pro teomics,2013,5 (6) :248-253.
  • 10Filippi-Chiela EC, Thornfi MP, Bueno E Silva MM, et al. Resveratrol abrogates the Temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the Temozolo- mide-indueed senescence in glioma cells[J]. BMC Cancer, 2013,4(13) :147- 154.

二级参考文献31

共引文献16

同被引文献20

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部